Illumina, Inc. ILMN and Kindstar Global (Kindstar) today
announced they are entering into a strategic collaboration whereby
Kindstar will validate and implement molecular assays in their
laboratories, leveraging Illumina's TruSightTM content sets,
Infinium® Dx CytoSNP-12 assay and NuPCRTM reagents. The
collaboration will enable Kindstar to expand its esoteric and specialty
testing services offerings within its network of more than 3,300
hospitals across China.
“Kindstar's adoption of Illumina's TruSight technology across its
extensive network in China speaks to the breadth and depth of content in
this innovative portfolio,” said Matt Posard, Senior Vice President and
General Manager of Illumina's Translational and Consumer Genomics
business. “Next-generation sequencing
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in